Kodiak Sciences to report phase 3 trial results Monday

Palo Alto, California - Kodiak Sciences Inc. (NASDAQ: KOD) is scheduled to reveal the key findings from its Phase 3 DAYBREAK study on Monday, September 28, as per a press release. The investigation assesses the efficacy of Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) in addressing wet age-related macular degeneration.

The biotech firm intends to conduct a webcast at 8:30 AM Eastern Time to present the results. Kodiak Sciences identifies itself as a precommercial retina-focused biotechnology enterprise. The company is currently engaged in three late-stage clinical endeavors, encompassing its entire portfolio. A webcast of this announcement will be accessible via the Events and Presentations segment on Kodiak’s investor relations website. Following the live presentation, an archived recording will remain available for a brief period.